检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]上海交通大学医学院附属第九人民医院口腔内科,上海200011 [2]上海市口腔医学研究所
出 处:《临床口腔医学杂志》2006年第3期178-180,共3页Journal of Clinical Stomatology
基 金:上海市卫生局科技发展基金(044005)
摘 要:目的:评价临床致病性口腔念珠菌感染的种类及对氟康唑、两性霉素B、5-氟胞嘧啶和伊曲康唑的药物敏感性,比较各种口腔黏膜病中的感染菌株的种类和耐药比例,为临床用药提供指导。方法:收集临床菌株,经YBC Test Kit鉴定其念珠菌种类;根据NCCLS的M27-A2标准方案测定3组(口腔念珠菌病、口腔扁平苔藓合并口腔念珠菌感染、头颈部放化疗患者合并口腔念珠菌感染)菌株对4种抗真菌药物的最低抑菌浓度,并比较不同口腔黏膜病合并念珠菌感染菌株的耐药状况。结果:68株临床分离株对5-氟胞嘧啶全部敏感,91.2%对两性霉素B敏感,氟康唑和伊曲康唑的耐药比例分别为13.2%和22.1%,放化疗组的非白色念株菌比例及耐药比例明显高于口腔念珠菌病组和扁平苔藓组。结论:口腔念珠菌感染菌株对氟康唑和伊曲康唑存在较高耐药比例和交叉耐药比例,头颈部肿瘤放疗或化疗患者口腔念珠菌感染菌株的非白色念株菌比例及耐药比例明显高于口腔念珠菌病和扁平苔藓合并口腔念珠菌感染菌株。Objective:To evaluate the sensitivity and resistance of pathogenic oral Candidaisolated from patients suffering from oral mucosal diseases(including head and neek cancer patients treated with radiotherapy or chemotherapy, Oral lichen planus, Oral Candidasis ) to antifungal agents. Method: Using YBC Test Kit to identification 68 clinical isolates of Candidas ; The in vitro susceptibilities of 68 oral Candida spp to amphoteritin B(AmB), 5-flueytosine(5-FC), itraeonazole (ICZ) and flueonazole were determined by NCCLS M27-A2 method. Result: All strains were sensitive to 5-flueytosine, 91.2% stains were semitive to amphoteritin B, 13.2% stains were resistant to flueonazole and 22.1% stains were resistant to itraconazole; The proportion of no-C. albieans and antifungal drug resistant strains isolated from head and neck cancer patients treated with radiotherapy or chemotherapy were higher than oral Candida spp isolated from oral lichen planus and oral Candidasis patients. Conclusion. The proportion of no-C. albieans and antifungal drug resistant strains in pathogenic oral Candida spp were pretty high,especially to strains isolated from head and neck cancer patients treated with radiotherapy or chemotherapy.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15